Citigroup

Citigroup’s Pelthos Therapeutics PTHS Stock Holding History

Citigroup’s Portfolio PTHS Stock Details PTHS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1	Closed	-$21	–	6319
2026 Q1	$21	Buy	+1	New	+$24	﹤0.01%	5695
2025 Q4	–	Sell	-1	Closed	-$28	–	6547
2025 Q3	$28	Buy	+1	New	+$24	﹤0.01%	5885

Other funds holding PTHS

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Vanguard Capital Management

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return

Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return

Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return

David M. Knott Jr $189M AUM 67.72% 1-Year Est. Return

Citigroup's PTHS Position: Q2 2026 in Review

Citigroup sold out of Pelthos Therapeutics (PTHS) in Q2 2026, closing a stake of 1 share — an estimated $21 sold.

Citigroup first reported a position in PTHS in Q3 2025 and held it in 2 quarters. The position peaked at $28 in Q3 2025. 24 funds tracked by Wall St. Rank hold PTHS as of Q2 2026.

Citigroup reported no remaining Pelthos Therapeutics position as of Q2 2026 after selling out during the quarter.
Citigroup sold 1 Pelthos Therapeutics share in Q2 2026, an estimated $21.
Citigroup first reported a position in Pelthos Therapeutics in Q3 2025 and held it in 2 quarters.
Citigroup's Pelthos Therapeutics position peaked at $28 in Q3 2025.
24 funds tracked by Wall St. Rank held Pelthos Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.